Temitope
Temitope Akinola
Fidson Healthcare Plc has indicated its intention to commission a N7.5 billion manufacturing plant later this year. This is to offer options in manufacturing and grow its product portfolio in Nigeria.
According to a statement by the company's Assistant Manager, Corporate Communications, Sylvester Iriogbe, the facility which is built to conform to the WorldHealth Organization (Geneva) current Good Manufacturing Practice (WHO-GMP) standards, would double the company's production capacity and will also for the first time, add intravenous fluids to Fidson's product portfolio.
He added that the company had continued to invest in research and development across various disease areas in order to achieve its strategic objective of consistently improving products and consolidate its market position in the nation's pharmaceutical industry.
Irogbe stated the result of this has brought the company to record a number of firsts, key among which was becoming the first company in Sub-Saharan Africa to manufacture anti-retroviral drugs in 2005. The company has also developed over 200 products which cut across several therapeutic classes including anti-effectives, gastrointestinal, antiretroviral, anti-malaria, cardiovascular, analgesic, haematinics, and supplements.
National Mirror
According to a statement by the company's Assistant Manager, Corporate Communications, Sylvester Iriogbe, the facility which is built to conform to the WorldHealth Organization (Geneva) current Good Manufacturing Practice (WHO-GMP) standards, would double the company's production capacity and will also for the first time, add intravenous fluids to Fidson's product portfolio.
He added that the company had continued to invest in research and development across various disease areas in order to achieve its strategic objective of consistently improving products and consolidate its market position in the nation's pharmaceutical industry.
Irogbe stated the result of this has brought the company to record a number of firsts, key among which was becoming the first company in Sub-Saharan Africa to manufacture anti-retroviral drugs in 2005. The company has also developed over 200 products which cut across several therapeutic classes including anti-effectives, gastrointestinal, antiretroviral, anti-malaria, cardiovascular, analgesic, haematinics, and supplements.
National Mirror